Small Pharma to Participate in Upcoming September Investor Conferences
Small Pharma Inc. (TSXV: DMT, OTCQB: DMTTF) will present at investor conferences this September, featuring CEO George Tziras and Chief Medical Officer Dr. Carol Routledge. The upcoming events include:
- H.C. Wainwright 24th Annual Global Investment Conference: Sept 12-14, 2022, virtual fireside chat.
- Jefferies Innovation in Mental Health Summit: Sept 22, 2022, in-person fireside chat in New York City.
Small Pharma focuses on developing DMT-assisted therapies for mental health, emphasizing short-acting psychedelics.
- None.
- None.
LONDON, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, announces that George Tziras, Chief Executive Officer and Dr. Carol Routledge, Chief Medical and Scientific Officer, will participate in upcoming investor conferences this September.
Details of the sessions are as follows:
H.C. Wainwright 24th Annual Global Investment Conference
Format: Fireside chat (virtual)
Date: September 12-14, 2022
Time: On-demand from 7:00 a.m. ET on Monday, September 12, 2022
Conference link: Webcast access here
Jefferies Innovation in Mental Health Summit, New York City
Format: Fireside chat (in person)
Date: September 22, 2022
Time: 8:30 a.m. ET
Conference link: TBA – please check back here for an update next week
To schedule a one-on-one meeting with Small Pharma’s management team, please contact your respective assigned conference representative or eric@lifesciadvisors.com.
The presentations and archived webcasts will also be accessible in the ‘Events and Conferences’ section of Small Pharma’s website following the conferences
About Small Pharma
Small Pharma is a biotechnology company progressing a pipeline of short-acting psychedelics with therapy for the treatment of mental health conditions, with a current focus on depression. Small Pharma initiated a clinical program into N, N-dimethyltryptamine (“DMT”) assisted psychotherapy in February 2021. This program includes a Phase I/IIa trial on the Company’s lead candidate alongside the development of a pipeline of proprietary preclinical assets.
About DMT
DMT is a naturally occurring psychedelic tryptamine found in plants and in the brain of mammals. Scientific evidence suggests DMT offers the potential for rapid-acting and long-lasting antidepressant effects. DMT is differentiated by its short psychedelic experience (< 30 mins), which allows for short treatment sessions and offers the potential for convenient supervised treatments within patient clinics.
For further information contact:
Small Pharma Inc.
George Tziras, Chief Executive Officer
Email: ir@smallpharma.co.uk
Tel: +1 (646) 751-4363
Investor Relations Contacts:
Eric Ribner
LifeSci Advisors
Email: eric@lifesciadvisors.com
Tel: +1 (646) 889-1200
Kristi Papanikolaw
KCSA Strategic Communications
Email: smallpharmair@kcsa.com
Tel: +1 (347) 487-6181
Media Relations Contacts:
USA - McKenna Miller
KCSA Strategic Communications
Email: smallpharmapr@kcsa.com
Tel: +1 (949) 949-6585
Rest of World - Jaber Mohamed
MHP Communications
Email: smallpharma@mhpc.com
Tel: +44 (0)7720 326 847
Cautionary Note
Small Pharma makes no medical, treatment or health benefit claims about its proposed products. The U.K. Medicines and Healthcare products Regulatory Agency (“MHRA”) or other similar regulatory authorities have not evaluated claims regarding DMT-assisted therapies and other next generation psychoactive compounds. The efficacy of such therapies has not been confirmed by MHRA-approved research. There is no assurance that such DMT-assisted therapies and other psychoactive compounds can diagnose, treat, cure or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. Any references to quality, consistency, efficacy and safety of potential therapies do not imply that Small Pharma verified such in clinical trials or that Small Pharma will complete such trials. If Small Pharma cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Small Pharma’s performance and operations.
The TSX Venture Exchange (the “TSXV”) has neither approved nor disapproved the contents of this news release. Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.
FAQ
What is Small Pharma Inc. focused on?
When is the H.C. Wainwright conference for Small Pharma?
What is the significance of DMT in Small Pharma's research?
Who will be representing Small Pharma at the conferences?
How can I view the conference presentations by Small Pharma?
